Index
A
Adverse Event Timeline, by severity 64–67, 113–116
analytical procedures, automatic graphs from 3
annotations 23–24, 161, 168
ARROW function 24
ASAT, distribution of by time and treatment 45–47, 173–176
attribute maps
about 25
GTL 160, 167
ATTRPRIORITY 151
automatic graphs, from analytical procedures 3
axes
defined 11, 163
in GTL 160
AXIS statement 15
AXISEXTENT option 113
AXISEXTENT=DATA option 109, 122
AXISTABLE statement 210, 211, 212, 224, 227, 228, 233
B
BAND statement 93
bands
box plot of QTc change from baseline with 91–92
lab test panel with 147–148
BARCHART statement 210
baseline
box plot of QTc change from 29–37, 89–94
panel of LFT shifts from to maximum by treatment 139–141
basic plots 22, 163
bivariate distribution plot 203–207, 236–240
BLOCK statement 142
BLOCKPLOT statement 199
box plot
lab test panel with 147–148
of QTc change from baseline 29–37, 89–94
BOXPLOT statement 210
butterfly plot, of cancer deaths by cause and gender 182–186, 218–222
C
categorical plots 164
categorization plots 22
cause, butterfly plot of cancer deaths by 182–186, 218–222
CDC chart, for length and weight percentiles 82–86, 132–136
cell 11, 162
Clark Error Grid 75–77, 125–127
COLAXIS statement 140, 146, 148
COLN() function 223
color graphs 6
COLORGROUP=DRUG option 90
COLORMODEL option 167
COLUMNLATTICE layout 20, 153, 154, 155
COLUMNWEIGHTS option 228
combining statements 22
COMPARE statement 10
conditional statements (GTL) 160
conditionals (GTL) 168
confidence plots 22
container, graph 165
Cravets, Matt 179, 216
CURVELABEL option 107
custom graphs
creating using Graph Template Language (GTL) 4
creating using ODS Graphics Designer application 5
creating using Statistical Graphics (SG) procedures 4
D
data sets, ODS styles and 5
DATALABEL option 187
DATALATTICE layout 166
DATAPANEL layout 166
DATATRANSPARENCY option 223
discrete axis, median of lipid profile by visit and treatment on 47–48, 101–102
DISCRETEATTRMAP statement 167, 229
DISCRETEATTRVAR statement 229
DISCRETELEGEND statement 178, 215
distribution
of ASAT by time and treatment 45–47, 98–101, 173–176, 211–212
of maximum LFT by treatment 72–74, 122–125
distribution plots 22, 164
draw statements 168
DRAWARROW statement 168
DRAWLINE statement 168
DRAWRECTANGLE statement 168
DRAWTEXT statement 168, 188, 189, 194, 199, 224, 225, 229, 233
DROPLINE statement 123
DYNAMIC statement 168
dynamic variables (GTL) 160, 167–168
E
END statement 177, 214
ENDGRAPH statement 177, 214
ENDLAYOUT statement 177, 214
entries (GTL) 160
ENTRY statement 168, 188–189, 192, 204, 224, 228, 238
entry statements (GTL) 167
ENTRYTITLE statement 159
expressions (GTL) 160, 168
external "Subjects At-Risk" table, survival plot with 50–52, 104–105
eye irritation, over time by severity and treatment 153–154
F
fit plots 22, 164
footnotes (GTL) 160, 167
forest plots
of hazard ratios by patient subgroups 191–197, 226–231
of impact of treatment on mortality by study 186–190, 222–226
functions
See specific functions
G
gender, butterfly plot of cancer deaths by 182–186, 218–222
Graph Template Language (GTL)
See also 9.3 GTL
See also 9.4 GTL
about 1, 157–158
annotate 168
attribute maps 167
conditionals 168
creating custom graphs using 4
draw statements 168
dynamic variables 167–168
entry statements 167
expressions 168
footnote statements 167
getting started 158–159
graphs and terminology 161–163
layout statements 165–166
legend statements 167
macro variables 167–168
plot statements 163–165
simple graph 159–161
title statements 167
graphs
defined 11, 162
GTL 161–163
simple GTL 159–161
grayscale
about 6
box plot of QTc change from baseline in 35–37, 93–94
Clark Error Grid in 76–77, 126–127
distribution of ASAT by time and treatment in 100–101
distribution of maximum LFT treatment in 124–125
immunology panel in 143–144
injection site reaction in 121–122
mean change in QTc by visit and treatment in 97–98
mean change in QTc by visit in 43–44
median of lipid profile by visit and treatment in linear axis in 102–103
median of lipid profile by visit and treatment on linear axis in 48–49
simple forest plot with study weights in 60–61, 110–111
survival plot with internal "Subjects At-risk" table in 53–54, 106–107
swimmer plot for tumor response in 80–81
swimmer plot for tumor response over time in 130–131
vital statistics for patient over time in 154
GRIDDED layout 166
group data, distribution of maximum LFT treatment in grayscale with 124–125
GROUPDISPLAY option 101–102
GROUPDISPLAY=CLUSTER option 90, 95
GTL (Graph Template Language)
See Graph Template Language (GTL)
H
hazard ratios, forest plot of by patient subgroups 191–197, 226–231
HIGHCAP option 66, 115
HIGHFLOW statement 42
HIGHLABEL option 193
HIGHLOW plot statement 62
HIGHLOWPLOT statement 193, 194
history, of ODS Graphics 1–2
I
IMAGE function 24
immunology profile, by treatment 142–144
INDENT option 112
injection site reaction 70–71, 120–122
in-line draw, in GTL 161
inner risk table, box plot of QTc change from baseline with 33–35, 91–92
inner table
mean change in QTc by visit and treatment with 96–97
mean change of QTc by week and treatment with 41–43
INNERMARGIN statement 227, 228
inset line name, lab test panel with 147–148
INSET statement 15, 86, 136, 148, 152
insets 11
INTERMARGIN statement 212
internal "Subjects At-risk" table, survival plot with 52–53, 53–54, 105–106, 106–107
ITEMSIZE option 220
K
KEYLEGEND statement 15, 90, 95
Kopicko, Jeff 179, 216
L
LATTICE layout 19, 150, 151, 155, 166
layering plots 15–16
LAYOUT LATTICE statement 172, 173–174, 177, 183, 187, 192, 198, 204, 210, 214
LAYOUT OVERLAY statement 172, 173–174, 177, 201, 210, 212, 214
layout statements
defined 163
GTL 165–166
layouts
in GTL 160
multi-cell ad hoc 166
single-cell 165–166
legend statements (GTL) 167
legends
defined 11, 163
GTL 160
length percentiles, CDC chart for 82–86, 132–136
LFT safety panel, baseline versus study 144–145
LFT shifts, panel of from baseline to maximum by treatment 139–141
LIFETEST procedure 3, 50–51, 198, 231–232
LINE function 24, 31
linear axis
median of lipid profile by visit and treatment in 102–103
median of lipid profile by visit and treatment on 48–49
LINELENGTH option 90, 102, 151
lipid profile, median of by visit and treatment 47–49
LOCATION=INSIDE option 93, 97, 106
LOCATION=OUTSIDE option 90, 95
LOWLABEL option 43, 66, 115, 193
M
macro variables (GTL) 160, 167–168
MARKERCHAR statement 42, 57, 62, 77, 172
MARKERCHARACTER option 174, 175, 180, 184, 187–188, 189, 194
MATRIX statement 10
maximum LFT by treatment, distribution of 72–74
mean change
in QTc by visit and treatment 94–98
in QTc by week and treatment 38–44
median, of lipid profile by visit and treatment 47–49, 101–103
%MODSTYLE() macro 25, 43, 49, 56, 68, 70, 77
multi-cell ad hoc layouts 166
multi-cell classification panels 11–12, 166
multi-cell comparative scatter plots 12
multi-column data, distribution of maximum LFT by treatment with 122–123
N
N() function 168
9.3 GTL
See also Graph Template Language (GTL)
See also SGPLOT procedure
about 171–172
bivariate distribution plot 203–207
butterfly plot of cancer deaths by cause and gender 182–186
distribution of ASAT by time and treatment 173–176
forest plot of hazard ratios by patient subgroups 191–197
forest plot of impact of treatment on mortality by study 186–190
most frequent on-therapy adverse events sorted by relative risk 176–178
product-limit survival estimates 197–202
treatment emergent adverse events with largest risk difference with NNT 179–182
9.3 SGPLOT procedure
about 28
adverse event timeline by severity 64–67
box plot of QTc change from baseline 29–37
CDC chart for length and weight percentiles 82–86
change in tumor size 67–69
Clark Error Grid 75–77
distribution of ASAT by time and treatment 45–47
distribution of maximum LFT by treatment 72–74
injection site reaction 70–71
mean change in QTc by week and treatment 38–44
median of lipid profile by visit and treatment 47–49
simple forest plot 55–61
subgrouped forest plot 62–64
survival plot 50–54
swimmer plot 77–81
9.4 GTL
See also Graph Template Language (GTL)
about 209–210
bivariate distribution plot 236–240
butterfly plot of cancer deaths by cause and gender 218–222
distribution of ASAT by time and treatment 211–212
forest plot of hazard ratios by patient subgroups 226–231
forest plot of impact of treatment on mortality by study 222–226
most frequent on-therapy adverse events sorted by relative risk 213–215
product-limit survival estimates 231–236
treatment emergent adverse events with largest risk difference with NNT 216–218
9.4 SGPLOT procedure
See also SGPLOT procedure
about 88
Adverse Event Timeline by severity 113–116
box plot of QTc change from baseline 89–94
CDC chart for length and weight percentiles 132–136
change in tumor size 117–119
Clark Error Grid 125–127
distribution of ASAT by time and treatment 98–101
distribution of maximum LFT by treatment 122–125
injection site reaction 120–122
mean change in QTc by visit and treatment 94–98
median of lipid profile by visit and treatment 101–103
simple forest plot 107–111
subgrouped forest plot 111–113
survival plot 104–107
swimmer plot 128–131
NNT
treatment emergent adverse events with largest risk difference with 179–182, 216–218
NOHEADER option, PANELBY statement 148, 152
O
ODS Graphics
about 1
history of 1–2
ODS Graphics Designer application
about 1
creating custom graphs using 5
ODS LISTING statement 36
ODS OUTPUT statement 198, 232
ODS styles, data sets and 5
OFFSETMAX option 189, 225
options
See specific options
outer risk table, box plot of QTc change from baseline with 29–32
outer table, mean change of QTc by week and treatment with 38–40
OVAL function 24, 31
OVERLAY layout 165
OVERLAYED layout 166
OVERLAYEQUATED layout 165
P
PAD option 30, 39
PANEL layout 18, 155
PANELBY statement, NOHEADER option 148, 152
parametric plots 164
PATTERN option 223
plot attributes, in GTL 161
PLOT statement 10
plot statements
defined 11, 162
GTL 163–165
plots
basic 163
categorical 164
categorization 22
confidence 22
distribution 22, 164
fit 22, 164
forest 186–190, 191–197, 222–226, 226–231
in GTL 160
layering 15–16
parametric 164
3-D 165
POLYGON function 24, 88
POLYLINE function 24
product-limit survival estimates 197–202, 231–236
PROTOTYPE layout 166
Q
QTc
box plot of change from baseline 29–37
mean change in by week and treatment 38–44
R
RANGEATTRMAP statement 167
RECTANGLE function 24
REFERENCELINE statement 188, 193, 194, 223
REFLINE statement 34, 58, 73, 113, 140, 141, 148
REGION layout 166
relative risk, most frequent on-therapy adverse events sorted by 176–178, 213–215
ROWAXIS statement 140
ROWHEIGHTS option 198
ROWLATTICE ;layout 21, 155
ROWWEIGHTS option 232
RUN statement 177, 214
S
SCATTER statement 39, 41, 43, 48, 56, 57, 58, 62, 95, 172, 187, 195, 210, 215
SCATTERPLOT statement 108, 174, 178, 180, 184, 188, 189, 194, 210, 223
SEPARATOR option 97
SERIES statement 38, 95
severity
adverse event timeline by 64–67
Adverse Event Timeline by 113–116
eye irritation over time by 153–154
SG
See Statistical Graphics (SG) procedures
SGANNO option 23, 30, 39, 46, 51
SGPANEL procedure
about 4, 10, 137–138
COLUMNLATTICE layout 20
eye irritation over time by severity and treatment 153–154
immunology profile by treatment 142–144
lab test for patient over time 148–150
lab test panel 146–148
LATTICE layout 19
LFT safety panel, baseline versus study 144–145
multi-cell classification panels using 11–12
PANEL layout 18
panel of LFT shifts from baseline to maximum by treatment 139–141
ROWLATTICE layout 21
syntax for 16–17
vital statistics for patient over time 150–152
SGPLOT procedure
See also 9.3 SGPLOT procedure
See also 9.4 SGPLOT procedure
about 4, 10
optional data roles for 14
plot options for 14
required roles for 14
single-cell graph using 10–11
syntax for 13
SGRENDER procedure 1, 158, 160, 167–168, 205, 239
SGSCATTER procedure
about 4, 10
multi-cell comparative scatter plots using 12
SIDEBAR statement 227
simple forest plot 55–61, 107–111
single-cell graph, using SGPLOT procedure 10–11
single-cell layouts 165–166
SPLITCHAR option 107
statements, combining 22
See also specific statements
StatGraph templates 4, 158, 165, 172
Statistical Graphics (SG) procedures
about 1, 9–10
annotation 23–24
automatic features 12–13
combining statements 22
creating custom graphs using 4
plot layering 15–16
SGPANEL 16–21
SGPLOT 13–14
styles 24–25
study days, lab test values by subject with 148–149, 149–150
study weights, simple forest plot with 59–61, 108–109, 110–111
STYLEATTRS statement 15, 25, 94, 98, 100, 109, 113, 118, 121, 122, 126, 143–144, 153
styles
GTL 161
SG (Statistical Graphics) procedures 24–25
subgrouped forest plot 62–64, 111–113
survival plot 50–54, 104–107
swimmer plot 77–81, 128–131
SYMBOLCHAR statement 15
SYMBOLIMAGE statement 15
T
TEMPLATE procedure 1, 4, 25, 157, 160, 172, 177, 210, 214
terminology (GTL) 161–163
TEXT statement 24, 31, 88, 108
3-D plots 165
TICKVALUEALIGN option 224
TICKVALUEPRIORITY option 228
time
distribution of ASAT by 45–47, 98–101, 173–176, 211–212
eye irritation over by severity and treatment 153–154
lab test for patient over 148–150
swimmer plot for tumor response over 77–79, 128–130, 130–131
vital statistics for patient over 150–152
titles (GTL) 160, 167
treatment
distribution of ASAT by 45–47, 98–101, 173–176, 211–212
distribution of maximum LFT by 72–74, 122–125
eye irritation over time by 153–154
forest plot of impact of on mortality by study 186–190
immunology profile by 142–144
mean change in QTc by 38–44, 94–98
mean of lipid profile by 47–49
median of lipid profile by 101–103
panel of LFT shifts from baseline to maximum by 139–141
tumor size, change in 67–69, 117–119
U
UNISCALE option 155
V
VALUES option 90
VALUESDISPLAY option 142
VBAR statement 69, 70, 119, 120
VBARPARM statement 69, 119
VBOX statement 34, 45, 72–73, 90, 123
visit
mean change in QTc by 94–98
mean of lipid profile by 47–49
median of lipid profile by 101–103
W
week, mean change in QTc by 38–44
weight percentiles, CDC chart for 82–86, 132–136
X
XAXIS statement 34, 45, 90
XAXISTABLE statement 88, 89, 90, 93, 95, 97, 99, 104, 106
XERRORLOWER option 228
XERRORUPPER option 228
Y
Y2AXIS statement 42, 43, 85, 135
YAXIS statement 34, 42, 85, 135, 136
YAXISOPTS 175, 189, 212, 225
YAXISTABLE statement 88, 108, 109, 112, 130